Phase i study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation

Transplantation

Volumn 88, Issue 11, 2009, Pages 1312-1318

  Orti, Guillermo ^a   Lowdell, Mark ^a   Fielding, Adele ^a   Samuel, Edward ^a   Pang, Kwok ^a   Kottaridis, Panos ^a   Morris, Emma ^b   Thomson, Kirsty ^b   Peggs, Karl ^b   MacKinnon, Stephen ^a   Chakraverty, Ronjon ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

CD8 T cell; Donor leukocyte infusion

Indexed keywords

ALEMTUZUMAB; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; LEUKOCYTE ANTIGEN; MELPHALAN;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; FEMALE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; HUMAN CELL; MALE; MANTLE CELL LYMPHOMA; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ALLOTRANSPLANTATION; APHERESIS; BLOOD AUTOTRANSFUSION; BLOOD DISEASE; CD4+ T LYMPHOCYTE; CELL SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOLOGY; IMMUNOMAGNETIC SEPARATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; TIME; TRANSPLANTATION; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; BLOOD COMPONENT REMOVAL; BLOOD TRANSFUSION, AUTOLOGOUS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOMAGNETIC SEPARATION; LONDON; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; TIME FACTORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73349138913     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181bbf382     Document Type: Article

References (36)

1. Kolb HJ, SchmidC, Barrett AJ, et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767.
2. Dazzi F, Szydlo RM, Apperley JF, et al. Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions. Blood 2002; 100: 2673.
3. Bloor AJ, Thomson K, Chowdhry N, et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 50.
4. + cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 2003; 101: 446.
5. Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100: 3108.
6. Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: Toxicity, chimerism, and disease responses. Blood 2004; 103: 1548.
7. Dey BR, McAfee S, Colby C, et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003; 9: 320.
8. Tomblyn M, Lazarus HM. Donor lymphocyte infusions: The long and winding road: How should it be traveled? Bone Marrow Transplant 2008; 42: 569.
9. Collins RH Jr, Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000; 26: 511.
10. Raiola AM, Van Lint MT, Valbonesi M, et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: A study on 593 infusions. Bone Marrow Transplant 2003; 31: 687.
11. van Rhee F, Savage D, Blackwell J, et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: Equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant 1998; 21: 1055.
12. Alyea E, Weller E, Schlossman R, et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: Induction of graft-versus-myeloma effect. Blood 2001; 98: 934.
13. Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4( + ) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998; 91: 3671.
14. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337.
15. + T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 2002; 8: 625.
16. Korngold R, Friedman TM, Jones SC. Animal Models of Graft-Vs.-Host Disease, ed. 3. New York, Marcel Dekker 2005.
17. Griffioen M, van der Meijden ED, Slager EH, et al. Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity. Proc Natl Acad Sci USA 2008; 105: 3837.
18. Meyer RG, Britten CM, Wehler D, et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 2007; 109: 374.
19. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071.
20. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825.
21. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267.
22. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419.
23. + T cells require direct leukemic contact to mediate GVL. Blood 2008; 111: 3884.
24. Merad M, Hoffmann P, Ranheim E, et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 2004; 10: 510.
25. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8: 575.
26. Collin MP, Hart DN, Jackson GH, et al. The fate of human Langerhans cells in hematopoietic stem cell transplantation. J Exp Med 2006; 203: 27.
27. Chu YW, Gress RE. Murine models of chronic graft-versus-host disease: Insights and unresolved issues. Biol Blood Marrow Transplant 2008; 14: 365.
28. Yamashita K, Choi U, Woltz PC, et al. Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. Blood 2004; 103: 3986.
29. Sakoda Y, Hashimoto D, Asakura S, et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood 2007; 109:1756.
30. + T cells generated de novo from donor hemopoietic stem cells mediate the evolution from acute to chronic graft-versus-host disease. J Immunol 2007; 179: 3305.
31. Chakraverty R, Eom HS, Sachs J, et al. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood 2006; 108: 2106.
32. + T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci USA 2003; 100: 1180.
33. Kawase T, Matsuo K, Kashiwase K, et al. HLA mismatch combinations associated with decreased risk of relapse: Implications for the molecular mechanism. Blood 2009; 113:2851.
34. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtu-zumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865.
35. Shaw BE, Byrne JL, Das-Gupta E, et al. The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants. Biol Blood Marrow Transplant 2007; 13: 550.
36. Miller JS, Weisdorf DJ, Burns LJ, et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood 2007; 110: 2761.